COMPANY PROFILE / #1163
Healx
Cambridge, United KingdomVenture Capital-Backed
OVERVIEW
Developer of an artificial intelligence-driven drug discovery technology designed to create treatments for rare diseases. The company offers a combination of frontier machine learning technology and drug discovery expertise, enabling clients to accelerate the development of novel treatments and improve the success rate for addressing the unmet needs of rare disease patients worldwide.
已融资133.73
最新估值275.91
员工数69
成立年份2014
公司概况
- Companies
- Healx
- Description
- Developer of an artificial intelligence-driven drug discovery technology designed to create treatments for rare diseases. The company offers a combination of frontier machine learning technology and drug discovery expertise, enabling clients to accelerate the development of novel treatments and improve the success rate for addressing the unmet needs of rare disease patients worldwide.
- Website
- www.healx.ai
- HQ Location
- Cambridge, United Kingdom
- Year Founded
- 2014
- Keywords
- community engagement, drug development, drug discovery technology, medical research, rare diseases data, small molecule
- Competitors
- onyx (Drug Discovery), Xaira Therapeutics, Aitia, Verge Analytics, Exscientia, Ignyta, Jounce Therapeutics, Biovista, Owkin, Merrimack Group, Redx Pharma, Recursion Pharmaceuticals, BioMarin Pharmaceutical, BenevolentAI, Onyx Pharmaceuticals, Sangamo Therapeutics, NexImmune, Adaptimmune Therapeutics, Genentech, Formation Bio, ImmunityBio, Coda Biotherapeutics, Agenus, NuCana, Inovio Pharmaceuticals, Vical, Alaunos Therapeutics, Oncorus, Senti Biosciences Holdings, Recombinetics, Genetix Biotherapeutics, TC Biopharm, Spark Therapeutics, Pharnext, Kite Pharma, InSilico Medicine Cayman
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 133.73
- First Financing Date
- 30-Apr-2014
- First Financing Size
- —
- First Financing Valuation
- —
- Last Financing Date
- 15-Jul-2025
- Last Financing Deal Type
- Later Stage VC
- Last Financing Size
- 2.00
- Last Financing Valuation
- —
- Last Financing Status
- Completed
- Last Known Valuation
- 275.91
- Last Known Valuation Date
- 01-Aug-2024
- Last Known Valuation Deal Type
- Later Stage VC
- Valuation Estimate
- 331.02
- Valuation Estimate Growth Rate
- 19.97%
- Active Investors
- 2468 Ventures, 333VC, 3e Capital Group, Amadeus Capital Partners, AstraZeneca, Atomico (UK) Partners, Ayana Capital, b2venture, Balderton Capital, Boehringer Ingelheim, Cambridge Enterprise Ventures, Cerebrum Tech Limited, Children's Tumor Foundation, Global Brain, Intel Capital, Jonathan Milner, Mandashi, Meltwind Advisory, ONO Pharmaceutical, Ovid Therapeutics, Pledge Ventures, SCI Ventures (London), Stevenage Bioscience Catalyst, Trend Investment Group, University of Cambridge, VU Venture Partners
- # Active Investors
- 26
- Acquirers
- —
团队与联系人
- Employees
- 69
- Employee Growth %
- -1.43% E
- Employee History
- 2026: 69, 2025: 70 E, 2024: 70, 2023: 71, 2022: 139, 2021: 80, 2020: 60, 2019: 42, 2018: 24, 2017: 19 E, 2016: 13
- Primary Contact
- Thomas Guilliams
- Primary Contact Title
- Co-Founder & Chief Executive Officer
- Primary Contact Email
- tim.guilliams@healx.io
- Primary Contact Phone
- +44 (0)12 2390 1980
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- -0.10%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 12
- Size Multiple
- 16.43x
- Size Multiple % Change
- 0.00%
- Size Multiple Change
- 0.00x
- Size Multiple Percentile
- 96
- Majestic Referring Domains
- 630
- SimilarWeb Unique Visitors
- 1,377
- SimilarWeb Unique Visitors Change
- 108
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 16%
- Success Probability Over Time – 3 Year
- 28%
- Success Probability Over Time – 5 Year
- 37%
记录来源：public.companies · 原始序号 #1163 · 所有字段均按数据库原值展示。